Background Prostate cancer patients with locoregional lymph node disease at diagnosis
(N1M0) still have a limited prognosis despite the improvements provided by aggressive …

Background High-risk localised prostate cancer (HRCaP) has high rates of biochemical
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …

Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to
test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone …

Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …

Management of prostate cancer (PC) might be improved by combining external beam
radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand …

Background Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177
Lu] Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of …

Results: A total of 248 therapy cycles were performed in 145 patients. Data for biochemical
response in 99 patients as well as data for physician-reported and laboratory-based toxicity …

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

Objective Investigators have extensively explored the short-term safety and efficacy data on
177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature …

177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer,
which could also be applied to patients with hormone-sensitive prostate cancer with high …